Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
--Trial to be used in support of NDA submission-- MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the Company initiated a...
MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at the 28th Annual J.P. Morgan Healthcare Conference...
MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has secured a committed equity financing facility under which it may sell...
MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at the Lazard Capital Markets 6th Annual Healthcare...
MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has completed a planned interim safety review of the open-label...
-- Analysis Shows Potential of LEVADEX to Treat a Broad Spectrum of Migraine -- -- Company to Host Webcast on Monday, September 14th at 7:15 a.m. ET -- MOUNTAIN VIEW, Calif., Sept. 10...
- Investor Webcast to Discuss Phase 3 LEVADEX(TM) Data Presented in Late-Breaking Session at the 14th Congress of the International Headache Society - MOUNTAIN VIEW, Calif., Sept. 2...
- Company to Suspend Development of UDB - MOUNTAIN VIEW, Calif., July 9 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has received a notice of...
MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that it has priced its initial public offering of 5,000,000 shares of common stock at a price of...
| Período | Var | Var % | Abe | Máx. | Mín. | Vol Méd. | VWAP diário | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| Nenhuma Discussão Encontrada |
| Criar Nova Discussão |
Suporte: (11) 4950 5808 | suporte@advfn.com.br
Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições
Recursos principais
Premium
